Clinical outcomes of pomalidomide‐based and daratumumab ...

Clinical outcomes of pomalidomide-based and daratumumab-based ...

In real-world settings, Pom-based, Dara-based, and DPd therapies exhibited favorable efficacy in patients with RRMM. Dara-based therapy yielded superior ...

Real-World Clinical Outcomes of Pomalidomide-Based and ...

However, there is limited data directly comparing Pom-based versus Dara-based therapies for relapsed/refractory multiple myeloma (RRMM) in either clinical ...

Clinical outcomes of pomalidomide‐based and daratumumab ...

5. CONCLUSIONS. Pom‐based, Dara‐based, and DPd therapies had favorable clinical efficacies in patients with RRMM. Dara‐based regimens were ...

Real-World Clinical Outcomes of Pomalidomide-Based and ...

Overall response rates (ORR) for Pom-based, Dara-based, and DPd groups were 54.3%, 83.9%, and 75.0%, respectively ( P = 0.03; Pom-based vs Dara- ...

Daratumumab-Based Therapeutic Approaches and Clinical ...

This retrospective review analyzed 112 patients who received daratumumab between 2012 and 2020. Tolerability, and efficacy based on prior lines (PL) of therapy ...

Pomalidomide/Daratumumab/Dexamethasone in Relapsed or ...

DPd resulted in favorable OS in patients with RRMM who had received prior LEN. •. IMiD agent-based therapy can still be considered after disease ...

(PDF) Clinical outcomes of pomalidomide-based and daratumumab ...

04, hazard ratio, 0.35, 95% CI, 0.28 to 0.97). The median overall survival was not reached. Important toxicities included anemia (28%), ...

Clinical outcomes of pomalidomide‐based and daratumumab ...

Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in ...

Clinical outcomes of retreatment with daratumumab-based regimens ...

Background: Daratumumab (Dara)-based regimens have resulted in deep responses and improved outcomes in newly diagnosed (NDMM) and ...

Full article: Pomalidomide, dexamethasone, and daratumumab ...

For patients with lenalidomide-refractory disease, these outcomes were 76.2%, 47.6%, and 23.7 months, respectively. No new safety signals were observed; 64.3% ...

Pomalidomide, dexamethasone, and daratumumab in relapsed ...

Patients with multiple myeloma who have relapsed after or become refractory to lenalidomide in early treatment lines represent a clinically ...

Continued support for daratumumab plus pomalidomide and ... - BJH

Based on the encouraging results of the APOLLO trial, the combination of intravenous daratumumab plus pomalidomide and dexamethasone was approved to treat R ...

Pomalidomide combinations are a safe and effective option after ...

Responses improved from 37% with daratumumab to 53% with pomalidomide. Of seven patients with extramedullary MM (EMM), four achieved a clinical ...

Clinical outcomes of pomalidomide-based and daratumumab-based ...

Article on Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world ...

Clinical Outcomes of Patients with Multiple Myeloma after ... - MDPI

Regarding the natural history of patients with refractory/relapsed MM after CD38 MoAB therapy, the median OS after daratumumab progression was ...

Daratumumab plus pomalidomide and dexamethasone in relapsed ...

Finally, pom-dex has demonstrated immune modulation, via activation of T cells, that correlated with clinical response,16 which could potentially complement the ...

Real-World Clinical Outcomes of Pomalidomide-Based and ...

However, subgroup analysis and interaction testing revealed that the PFS improvement with Dara-based versus Pom-based therapies was more pronounced among ...

ineligible patients who are newly diagnosed with multiple myeloma

The rates of deep and sustained MRD negativity were associated with improved progression-free survival (PFS) with DARZALEX FASPRO®-based ...

Clinical efficacy of daratumumab, pomalidomide, and ...

The results of this retrospective analysis highlight the safety and efficacy of the DARA-POM-D regimen in treating patients with RRMM who are ...

Paper: Economic Evaluation of Daratumumab and Pomalidomide ...

Phase II/III clinical trials showed that isatuximab (ISA) or daratumumab (DARA) in combination with pomalidomide (POM-d) and low-dose dexamethasone (DEXA) ...